Search results
Showing 286 to 300 of 456 results for learning disabilities
NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
View recommendations for TA217Show all sections
This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.
Cochlear implants for children and adults with severe to profound deafness (TA566)
Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (DG60)
Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD)
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
adults, homeless people, those with severe mental illness, learning or physical disabilities, prisoners, refugees, recent...
NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
View recommendations for CG153Show all sections
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.